Why I'd buy and hold CSL shares forever

CSL Limited (ASX: CSL) shares have been surging higher for decades, but here's why I think it's one to buy and hold forever…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares have consistently outperformed in recent decades. The Aussie biotech giant listed in 1994 for a stock-split-adjusted price of $0.76 per share. Given its current share price of $301.18 per share, that means a $10,000 IPO investment would have netted you a 40,000% return on investment. Not bad, hey?

Why CSL shares have rocketed higher

The CSL share price gains have been built on steady expansion and successful research and development. The biotech giant is everywhere in pharmaceuticals and the medical sector with a strong track record.

Investors have come along for the ride with CSL shares surging higher. Even when ASX 200 shares were hammered in March and April, CSL held its value.

In fact, shares in the biotech giant have climbed higher in 2020. Given the S&P/ASX 200 Index (ASX: XJO) is down nearly 20% in the same period, I'd say CSL is a strong defensive buy.

That's just one of the reasons why I'd consider CSL to be an investment to buy and hold forever.

Why I'd buy and hold CSL shares forever

Apart from a history of capital gains, I think CSL offers a number of good qualities. The group's earnings are non-cyclical which can be handy when times get tough.

On top of that, CSL shares have a handy dividend yield of 0.97%. While that's far from what's offered by the A-REITs or other top ASX dividend shares, it's still a good income boost. That's particularly the case when you consider CSL shares are worth around $300 each.

On top of dividends, CSL still has strong growth potential ahead. Normally, there's a trade-off between paying dividends and reinvesting for future capital gains. However, CSL could offer investors a magic combination of both.

The Aussie biotech group has a significant market share and a promising R&D pipeline. If the company can bring some of its best products to market in the coming years, I'd say its share price could be climbing higher.

This includes developing a potential COVID-19 treatment announced in conjunction with the Federal Government. CSL will seek plasma donations from 800 people who have recovered from COVID-19 to continue work on a potential treatment for the virus.

Foolish takeaway

CSL shares have a strong history of capital growth and also have a handy dividend. With non-cyclical earnings and a $137 billion market capitalisation, I think CSL could be one to buy and hold forever.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »